393 related articles for article (PubMed ID: 102587)
21. Ability of complement to release systemic lupus erythematosus immune complexes from cell receptors.
Medof ME; Scarborough D; Miller G
Clin Exp Immunol; 1981 May; 44(2):416-25. PubMed ID: 7307341
[TBL] [Abstract][Full Text] [Related]
22. Regulation of immune complex-mediated complement activation by autoantibodies (F-42) isolated from sera of patients with systemic lupus erythematosus.
Daha MR; Hazevoet HM; Vanes LA
Clin Exp Immunol; 1983 Sep; 53(3):541-6. PubMed ID: 6604604
[TBL] [Abstract][Full Text] [Related]
23. A comparative study of complement components in polyethylene glycol precipitated immune complexes from patients with ovarian cancer and patients with rheumatoid arthritis.
Mooney NA; Hay FC; Poulton TA
Clin Exp Immunol; 1983 Jun; 52(3):561-8. PubMed ID: 6603297
[TBL] [Abstract][Full Text] [Related]
24. The development of a C1q anti-C1q immunoadsorbent for removal of immune complexes from plasma.
Bratt T; Ohlson S
J Clin Lab Immunol; 1988 Dec; 27(4):191-5. PubMed ID: 3266946
[TBL] [Abstract][Full Text] [Related]
25. The complement-mediated binding of soluble antibody/dsDNA immune complexes to human neutrophils.
Taylor RP; Burge J; Horgan C; Shasby DM
J Immunol; 1983 Jun; 130(6):2656-62. PubMed ID: 6854016
[TBL] [Abstract][Full Text] [Related]
26. Reaction of immune complexes with Hodgkin's disease tissue cultures: radioimmune assay and immunoferritin electron microscopy.
Long JC; Dvorak AM; Quay SC; Stamatos C; Chi SY
J Natl Cancer Inst; 1979 Apr; 62(4):787-97. PubMed ID: 372654
[TBL] [Abstract][Full Text] [Related]
27. Complement receptor expression by neoplastic and normal human cells.
Gaither TA; Magrath IT; Berger M; Hammer CH; Novikovs L; Santaella M; Frank MM
J Immunol; 1983 Aug; 131(2):899-905. PubMed ID: 6306108
[TBL] [Abstract][Full Text] [Related]
28. The complement fixing ability of putative circulating immune complexes in rheumatoid arthritis and its relationship to extra-articular disease.
Bourke BE; Moss IK; Mumford P; Horsfall A; Maini RN
Clin Exp Immunol; 1982 Jun; 48(3):726-32. PubMed ID: 6981475
[TBL] [Abstract][Full Text] [Related]
29. Application of the solid phase C1q and Raji cell radioimmune assays for the detection of circulating immune complexes in glomerulonephritis.
Tung KS; Woodroffe AJ; Ahlin TD; Williams RC; Wilson CB
J Clin Invest; 1978 Jul; 62(1):61-72. PubMed ID: 659639
[TBL] [Abstract][Full Text] [Related]
30. C1q inhibits the expression of B lymphoblastoid cell line interleukin 1 (IL 1).
Habicht GS; Beck G; Ghebrehiwet B
J Immunol; 1987 Apr; 138(8):2593-7. PubMed ID: 3494080
[TBL] [Abstract][Full Text] [Related]
31. Purification of soluble immune complexes from serum using polymethylmetacrylate beads coated with conglutinin or C1q. Application to the analysis of the components of in vitro formed immune complexes and of immune complexes occurring in vivo during leishmaniasis.
Casali P; Lambert PH
Clin Exp Immunol; 1979 Aug; 37(2):295-309. PubMed ID: 498587
[TBL] [Abstract][Full Text] [Related]
32. Binding of model immune complexes to erythrocyte CR1 facilitates immune complex uptake by U937 cells.
Emlen W; Burdick G; Carl V; Lachmann PJ
J Immunol; 1989 Jun; 142(12):4366-71. PubMed ID: 2524529
[TBL] [Abstract][Full Text] [Related]
33. Purification and characterization of the 1q subcomponent of canine complement and its use in the 125I-C1q binding assay for detection of immune complexes.
Wu CC; Bey RF; Loken KI
Am J Vet Res; 1988 Jun; 49(6):865-9. PubMed ID: 3135770
[TBL] [Abstract][Full Text] [Related]
34. Native C3 does not bind to the C3b receptor (CR1) of human blood B lymphocytes or alter immunoglobulin synthesis.
Berger M; Fleisher TA
J Immunol; 1983 Mar; 130(3):1021-3. PubMed ID: 6600466
[TBL] [Abstract][Full Text] [Related]
35. Characterization of C1q by monoclonal antibodies.
Heinz HP; Loos M
Behring Inst Mitt; 1984 Nov; (76):42-58. PubMed ID: 6335397
[TBL] [Abstract][Full Text] [Related]
36. Generation of low m.w., C3-bearing immunoglobulin in human serum.
Jacobs RJ; Reichlin M
J Immunol; 1983 Jun; 130(6):2775-81. PubMed ID: 6602181
[TBL] [Abstract][Full Text] [Related]
37. Qualitative and quantitative assessment of C3-receptor reactivities on lymphoid and phagocytic cells.
Schmitt M; Mussel HH; Dierich MP
J Immunol; 1981 May; 126(5):2042-7. PubMed ID: 7217681
[TBL] [Abstract][Full Text] [Related]
38. C3, C4, and the terminal complement complex differ from C1q by binding predominantly to the antigenic part of solid phase immune complexes.
Garred P; Michaelsen TE; Aase A; Mollnes TE
J Immunol; 1990 Jan; 144(1):198-203. PubMed ID: 2295791
[TBL] [Abstract][Full Text] [Related]
39. Covalent binding of C3b to monoclonal antibodies selectively up-regulates heavy chain epitope recognition by T cells.
Santoro L; Drouet C; Reboul A; Mach JP; Colomb MG
Eur J Immunol; 1994 Jul; 24(7):1620-6. PubMed ID: 8026522
[TBL] [Abstract][Full Text] [Related]
40. Interaction of human lymphocytes with fluid phase human C3b detected by immunofluorescence.
Simonian S; Molenaar JL; Zeijlemaker WP; Knape JT; Bakker S; Pondman KW
Eur J Immunol; 1976 Jan; 6(1):52-6. PubMed ID: 823035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
